Terms: = Uterine cancer AND CALCB, Calcitonin AND Treatment
14 results:
1. Hypercalcemic crisis in third trimenon: evaluating the optimal treatment strategy.
Refardt J; Farina P; Hoesli I; Meier C
Gynecol Endocrinol; 2018 Oct; 34(10):833-836. PubMed ID: 29658374
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
Valverde P
Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
[TBL] [Abstract] [Full Text] [Related]
3. Neuroendocrine tumor metastasis to the thyroid gland.
Yamada H; Hasegawa Y; Mitsudomi T; Nakashima T; Yatabe Y
Int J Clin Oncol; 2007 Feb; 12(1):63-7. PubMed ID: 17380445
[TBL] [Abstract] [Full Text] [Related]
4. Skin temperature rise induced by calcitonin gene-related peptide in gonadotropin-releasing hormone analogue-treated female rats and alleviation by Keishi-bukuryo-gan, a Japanese herbal medicine.
Noguchi M; Ikarashi Y; Yuzurihara M; Kase Y; Watanabe K; Plotnikoff GA; Takeda S; Aburada M
Life Sci; 2005 Mar; 76(18):2079-90. PubMed ID: 15826875
[TBL] [Abstract] [Full Text] [Related]
5. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism.
Nakayama H; Yano T; Sagara Y; Ando K; Kasai Y; Taketani Y
Endocr J; 1997 Aug; 44(4):479-84. PubMed ID: 9447279
[TBL] [Abstract] [Full Text] [Related]
6. Postmenopausal hormone replacement therapy--clinical implications.
Ravn SH; Rosenberg J; Bostofte E
Eur J Obstet Gynecol Reprod Biol; 1994 Feb; 53(2):81-93. PubMed ID: 8194655
[TBL] [Abstract] [Full Text] [Related]
7. [Substitutive hormone therapy in postmenopausal osteoporosis. Are there any contraindications?].
Taurelle R
Rev Fr Gynecol Obstet; 1993; 88(7-9):430-4. PubMed ID: 8235258
[TBL] [Abstract] [Full Text] [Related]
8. [Bone mineral content in premenopausal women treated with gonadotropin-releasing hormone analogue].
Masahashi T; Negoro Y; Asai M; Suzuki M; Noguchi M; Nakanishi M; Tomita A
Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):577-80. PubMed ID: 1619317
[TBL] [Abstract] [Full Text] [Related]
9. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
Ito M; Sakoda Y; Okamura H
Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
[TBL] [Abstract] [Full Text] [Related]
10. [Monotherapy with clodronate for tumor-induced hypercalcemia].
Harjung H; Fritze D
Dtsch Med Wochenschr; 1990 Jan; 115(2):48-52. PubMed ID: 2136827
[TBL] [Abstract] [Full Text] [Related]
11. Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy.
Schiogolev SA; Goetzl EJ; Urba WJ; Longo DL
J Clin Immunol; 1989 Mar; 9(2):169-73. PubMed ID: 2469694
[TBL] [Abstract] [Full Text] [Related]
12. LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation.
Cirkel U; Schweppe KW; Ochs H; Hanker JP; Schneider HP
Arch Gynecol Obstet; 1989; 246(3):139-51. PubMed ID: 2515811
[TBL] [Abstract] [Full Text] [Related]
13. Estrogen and bone. Marshall R. Urist's contributions.
Gordan GS
Clin Orthop Relat Res; 1985 Nov; (200):174-80. PubMed ID: 3905109
[TBL] [Abstract] [Full Text] [Related]
14. Estrogen replacement therapy: indications and complications.
Judd HL; Meldrum DR; Deftos LJ; Henderson BE
Ann Intern Med; 1983 Feb; 98(2):195-205. PubMed ID: 6824255
[TBL] [Abstract] [Full Text] [Related]
